Roche licenses Rona Therapeutics ALK7-targeting RNAi obesity therapy in deal worth up to $1.16 billion
Roche has secured worldwide rights to Rona Therapeutics' investigational ALK7-targeting RNAi therapy in an obesity and metabolic disease licensing agreement worth up to $1.16 billion.
The agreement covers an RNA interference candidate designed to target ALK7 using Rona's extrahepatic delivery technology, with the aim of developing a differentiated approach to metabolic disease treatment.
Rona may receive up to $100 million in upfront and near-term payments, up to $1.06 billion in subsequent milestones and royalties, while the candidate's proposed effects on visceral fat and lean mass remain to be established clinically.
Field | Content |
Article Type | Deals |
Companies | Roche; Rona Therapeutics |
Deal Type | Exclusive worldwide licensing agreement |
Potential Deal Value | Up to $1.16 billion excluding royalties |
Upfront and Near-Term Payments | Up to $100 million combined |
Subsequent Milestones | Up to $1.06 billion |
Royalties | Additional royalties; rates not disclosed in supplied summary |
Licensed Asset | Investigational ALK7-targeting RNAi therapeutic candidate |
Molecular Target | ALK7 |
Technology | RNA interference with extrahepatic delivery |
Therapeutic Modality | RNAi therapy |
Therapeutic Areas | Obesity and metabolic diseases |
Development Stage | Investigational; clinical development status not specified in supplied summary |
Licensing Rights | Exclusive global rights obtained by Roche |
Geography | Worldwide |
What Happened | Roche entered a global licensing agreement for Rona Therapeutics' ALK7-targeting RNAi candidate. |
Why It Matters | The collaboration broadens Roche's obesity and metabolic disease pipeline with a gene-silencing approach directed at adipose tissue biology. |
Strategic Rationale | Roche gains access to an investigational metabolic target and Rona's delivery technology while Rona receives near-term funding and contingent milestone opportunities. |
Potential Impact | The candidate could offer a differentiated obesity treatment strategy if its proposed metabolic benefits are confirmed in clinical studies. |
Key Takeaway | Roche's agreement with Rona carries potential payments of up to $1.16 billion plus royalties; efficacy and safety remain investigational. |
What to Watch | Clinical development plans, human efficacy and safety data, delivery performance and milestone payments. |
Primary Source | Rona Therapeutics announcement |
Relevant Date | 13 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires